Obstructive Sleep Apnea Pipeline | 20+ Key Players & 20+ Pipeline Drugs | FDA, EMA, and PMDA Approvals, Clinical Trials

DelveInsight's, "Obstructive Sleep Apnea Pipeline Insight 2023" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Obstructive Sleep Apnea (OSA) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Obstructive Sleep Apnea Pipeline Report
• DelveInsight's Obstructive Sleep Apnea pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Obstructive Sleep Apnea treatment.
• The leading Obstructive Sleep Apnea Companies are working such as Apnimed, Therapix Biosciences, Eisai, Idorsia Pharmaceuticals, Takeda, Merck & Co, Taisho Pharmaceutical Co., Ltd., Bayer, Janssen Pharmaceuticals, RespireRx Pharmaceuticals, Cortex Pharmaceuticals, Michael James Enterprises, and others.
• Promising Obstructive Sleep Apnea Pipeline therapies such as Lemborexant, Sulthiame, AD 182, TAK-925, and others.
• The Obstructive Sleep Apnea Companies and academics are working to assess challenges and seek opportunities that could influence Obstructive Sleep Apnea R&D. The therapies under development are focused on novel approaches to treat/improve Obstructive Sleep Apnea

Recent Developmental Activities in the Obstructive Sleep Apnea Pipeline
• Lemborexant, is an orexin receptor antagonist that blocks the receptors involved in the regulation of sleep and wakefulness. It is expected to alleviate wakefulness, thereby facilitating faster onset and maintenance of sleep. The drug has recently completed the Phase I trial for the Obstructive Sleep Apnea.
• Sulthiame is an investigational drug. There have been 4 clinical trials for Sulthiame. The most common disease conditions in clinical trials are Epilepsy, Epilepsy, Rolandic, and Sleep Apnea, Obstructive. Currently the drug is in Phase II for the treatment of Obstructive Sleep Apnea.
• AD109 is a first-in-class, oral pharmaceutical combination dosed once-daily at bedtime, designed to treat OSA patients across a broad spectrum of disease severity. AD109 combines a selective norepinephrine reuptake inhibitor (NRI), atomoxetine, with a novel NCE selective antimuscarinic, aroxybutynin. The investigational drug is designed to be safe, effective, and convenient, addressing the key limitations of the current standard of care treatments. AD036 improved multiple objective measures of OSA as well as OSA symptoms, providing proof-of-concept that an oral pharmacologic approach may have clinical benefit in patients with OSA.
• TAK-925, being studied as an orexin agonist which works selectively on orexin 2 receptors, in sleep-wake disorders characterized by excessive daytime sleepiness (EDS). TAK-925, demonstrated a statistically significant improvement in mean sleep latency measured by the Maintenance of Wakefulness Test (MWT) versus placebo. Currently, the drug is in Phase I stage of development for the treatment of OSA.

Request a sample and discover the recent advances in Obstructive Sleep Apnea treatment drugs @ Obstructive Sleep Apnea Pipeline Outlook Report- https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Obstructive Sleep Apnea Overview
Obstructive sleep apnea (OSA) is characterized by episodes of breathing cessation or shallow breathing in sleep. These episodes are due to complete or partial collapse of upper airway. Most of the time, the respiratory events are associated with snoring, oxygen desaturations and brief arousal from sleep. Sleep apnea is usually worse during supine and Rapid Eye Movement (REM) sleep. There could be exacerbation of snoring and OSA with alcohol consumption or ingestion of sedative medications. OSA is common and the prevalence is increasing with the increased prevalence of obesity. Daytime sleepiness is among the most common symptoms, but many patients with OSA are asymptomatic. Patients with OSA who are asymptomatic, or whose symptoms are minimally bothersome and pose no apparent risk to driving safety, can be treated with behavioral measures, such as weight loss and exercise.

Obstructive Sleep Apnea Pipeline Insight Report
In the Obstructive sleep apnea pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Obstructive Sleep Apnea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Obstructive Sleep Apnea Emerging Drugs
• Lemborexant : Eisai
• Sulthiame : Desitin Arzneimittel GmbH
• AD 182 : Apnimed
• TAK-925 : Takeda

Find out more about Drugs for Obstructive Sleep Apnea Therapies @ Obstructive Sleep Apnea Treatment Landscape- https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Obstructive Sleep Apnea Pipeline Therapeutic Analysis
There are approx. 20+ key companies which are developing the therapies for Obstructive Sleep Apnea. The companies which have their Obstructive Sleep Apnea drug candidates in the most advanced stage, i.e. phase II include, Desitin Arzneimittel GmbH.

Scope of the Obstructive Sleep Apnea Pipeline Report
• Coverage- Global
• Obstructive Sleep Apnea Companies- Apnimed, Therapix Biosciences, Eisai, Idorsia Pharmaceuticals, Takeda, Merck & Co, Taisho Pharmaceutical Co., Ltd., Bayer, Janssen Pharmaceuticals, RespireRx Pharmaceuticals, Cortex Pharmaceuticals, Michael James Enterprises, and others.
• Promising Obstructive Sleep Apnea Pipeline therapies- Lemborexant, Sulthiame, AD 182, TAK-925, and others
• Obstructive Sleep Apnea Key Companies, Key Products, Unmet Needs

Explore more information about the Obstructive Sleep Apnea Companies, Therapies, Key Products, Unmet Needs @ https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Obstructive Sleep Apnea: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Obstructive Sleep Apnea- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name : Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Sulthiame : Desitin Arzneimittel GmbH
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name : Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Obstructive Sleep Apnea Key Companies
21. Obstructive Sleep Apnea Key Products
22. Obstructive Sleep Apnea- Unmet Needs
23. Obstructive Sleep Apnea- Market Drivers and Barriers
24. Obstructive Sleep Apnea- Future Perspectives and Conclusion
25. Obstructive Sleep Apnea Analyst Views
26. Obstructive Sleep Apnea Key Companies
27. Appendix

For further information on the Obstructive Sleep Apnea pipeline therapeutics, reach out @ Obstructive Sleep Apnea Companies- https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Yash Bhardwaj

info@delveinsight.com

This release was published on openPR.